Global Market Report for Electronic Nicotine Delivery Systems (ENDS)

Aug.16.2022
Global Market Report for Electronic Nicotine Delivery Systems (ENDS)
The global market for electronic nicotine delivery systems, including e-cigarettes, is predicted to grow rapidly through 2026.

The Business Research Company has released a market research report that predicts the size and trends of the global market for electronic nicotine delivery systems, including e-cigarettes, from 2022 to 2026.


According to a global market report by a business research company, the vaporizer, electronic cigarette, and other electronic nicotine delivery systems (ENDS) market is expected to grow from $19.92 billion in 2021 to $25.03 billion in 2022, with a compound annual growth rate (CAGR) of 25.6%. The market growth is mainly due to companies resuming operations and adapting to a new normal, while recovering from the impact of COVID-19, which earlier resulted in restrictive measures including social distancing, remote work, and the closure of commercial activities, posing operational challenges. The vaporizer, electronic cigarette, and other ENDS market is expected to reach $55.99 billion in 2026, with a CAGR of 22.3%. The awareness of health issues caused by traditional cigarettes among smokers is driving the growth of the electronic cigarette market.


The main trends in the market for vaporizers, electronic cigarettes, and other electronic nicotine delivery systems (ENDS) are as follows: There is an increasing demand for medicinal cannabis vaporizers in the vaporizer market. Cannabis vaporizers have controlled heating technology and can precisely adjust heating temperature through the display screen on the device, allowing users to fully control the density of the aerosol produced. The TBRC's 2022 Global Market Report on Vaporizers, Electronic Cigarettes, and Other Electronic Nicotine Delivery Systems (ENDS) includes the following information:


This report categorizes the market based on geographical regions including the Asia Pacific, China, Western Europe, Eastern Europe, North America, the United States, South America, the Middle East, and Africa. It also reflects segmentation by country, including Australia, Brazil, mainland China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the United Kingdom, and the United States, as well as by product type, including atomizers, e-cigarettes, and other electronic nicotine delivery systems. Within these product categories, e-cigarettes can be further divided into disposable, rechargeable, and modular types, while atomizers include e-cigarette atomizers, cannabis atomizers, and medical atomizers. The global market for e-cigarettes and other ENDS can be segmented geographically into North America, South America, the Asia Pacific, Eastern Europe, Western Europe, the Middle East, and Africa. The APAC region holds the largest market share. Leading market players mentioned in the report include Dash Vapes, Hubbly Bubbly, Liquideu, Nice Vapor, Pacific Smoke International, Puff Ecig, Simple Vape Co. London Ltd, Smokio, Vape Escapes, and Vapor Line. The report also highlights current trends, opportunities, strategies, and more. Disclaimer:


This article is compiled from third-party information and is intended only for industry exchange and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness or accuracy of the content. The compilation of this article is only intended for industry exchanges and research purposes.


Due to the limitations of the translation skills, the translated article may not fully express the original meaning. Please refer to the original text for accuracy.


In terms of any domestic, Hong Kong, Macau, Taiwan, or foreign-related expressions and positions, 2FIRSTS is fully aligned with the Chinese government.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona's First Things First is pushing for an excise tax equal to 50% of the retail price of vaping products, estimating that the measure could generate about $100 million annually. The agency says its tobacco-tax revenue has fallen 47% from 2008 levels. Arizona has attempted to broaden its nicotine tax base in each of the past two years: a 2025 bill proposed a 50% wholesale-price tax, while a 2026 measure shifted to a 50% retail-price tax covering alternative nicotine products and vapor products. Separately, the state enacted HB 4001 this year to establish a new licensing and sales framework for alternative nicotine products.
Sep.21
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
BAT Adds Former Apple General Counsel Bruce Sewell to Board as Finance, Legal, Marketing and Regional Leadership Shift
BAT Adds Former Apple General Counsel Bruce Sewell to Board as Finance, Legal, Marketing and Regional Leadership Shift
British American Tobacco has appointed former Apple Senior Vice President, General Counsel and Secretary Bruce Sewell as an independent non-executive director, effective January 1, 2027. He will also join BAT's Audit and Nominations Committees. BAT Chair Luc Jobin highlighted Sewell's experience in technology, government and regulatory affairs, public-company governance and AI-company boards. Over the past 18 months, BAT has changed or announced changes to its CFO, general counsel, CMO and APMEA regional leadership, while the main board has also seen multiple changes. The appointment comes as BAT advances Horizon 2030 and its Fit2Win transformation while expanding New Categories and reshaping parts of its digital, technology and operating structure.
Business
Oct.29
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07